[1]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,(13):142-143.[doi:10.3969/j.issn.1006-1959.2018.13.042]
 HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,(13):142-143.[doi:10.3969/j.issn.1006-1959.2018.13.042]
点击复制

曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2018年13期
页码:
142-143
栏目:
药物与临床
出版日期:
2018-07-01

文章信息/Info

Title:
Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure
文章编号:
1006-1959(2018)13-0142-02
作者:
何玲玲程淑芬
解放军第四五二医院内四科,四川 成都 610021
Author(s):
HE Ling-lingCHENG Shu-fen
Department of Internal Medicine,Subject Four,the 452 Hospital of PLA,Chengdu 610021,Sichuan,China
关键词:
冠心病心力衰竭曲美他嗪琥珀酸美托洛尔
Keywords:
Key words:Coronary heart diseaseHeart failureTrimetazidineMetoprolol succinate
分类号:
R541
DOI:
10.3969/j.issn.1006-1959.2018.13.042
文献标志码:
A
摘要:
目的 观察冠心病心力衰竭患者施予曲美他嗪与琥珀酸美托洛尔联合治疗的效果。方法 将本院收治的120例冠心病心力衰竭患者随机分为A组与B组,各60例。A组行常规治疗,B组在A组基础上施予曲美他嗪与琥珀酸美托洛尔联合治疗,比较两组的临床疗效及治疗前后患者的心肌功能情况。结果 治疗后B组患者LVEDD、LVESD、DBF、SBF低于A组,LVEF高于A组,差异有统计学意义(P<0.05);A组总有效率为81.67%,低于B组的96.67%,差异有统计学意义(P<0.05)。结论 曲美他嗪与琥珀酸美托洛尔联合治疗冠心病心力衰竭,临床效果显著,可有效改善患者心肌功能。
Abstract:
Abstract:Objective To observe the effect of combined treatment with trimetazidine and metoprolol succinate in patients with coronary heart disease and heart failure.Methods 120 patients with coronary heart disease admitted to our hospital were randomly divided into group A and group B,60 cases in each group.Group A was treated routinely.Group B was treated with combination of trimetazidine and metoprolol succinate on the basis of group A.The clinical efficacy of the two groups and the myocardial function of the patients before and after treatment were compared.Results After treatment,LVEDD,LVESD,DBF and SBF were lower in group B than in group A,and LVEF was higher than that in A group,the difference was statistically significant(P<0.05),and the total effective rate of group A was 81.67%,lower than that of group B 96.67%,and the difference was statistically significant(P<0.05).Conclusion Trimetazidine combined with metoprolol succinate is effective in treating coronary heart disease with heart failure.It can effectively improve myocardial function in patients with coronary heart disease.

参考文献/References:

[1]苏大为.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭患者50例临床观察[J].甘肃科技,2017,33(21):103-104. [2]王静,李伟,张良胜.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察[J].中国现代药物应用,2016,10(05):103-104. [3]伍莉.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察[J]. 世界最新医学信息文摘,2016,16(78):18-19. [4]陈穗琛,钱万桥.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者的疗效观察[J].慢性病学杂志,2016,17(06):663-665. [5]郭晋元.美托洛尔联合曲美他嗪治疗冠心病心力衰竭患者临床疗效观察[J].中国社区医师,2016,32(33):23-24.

相似文献/References:

[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
 GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,(13):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]袁 帅,邢晓博,李 晓,等.MTHFR基因多态性与中年男性冠状动脉病变程度的相关研究[J].医学信息,2018,(03):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
 YUAN Shuai,XING Xiao-bo,LI Xiao,et al.Association of MTHFR Gene Polymorphism with Coronary Artery Lesions in Middle-aged Men[J].Medical Information,2018,(13):67.[doi:10.3969/j.issn.1006-1959.2018.03.021]
[3]张挺挺.经股和桡动脉介入治疗冠心病的临床疗效对比[J].医学信息,2018,(03):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
 ZHANG Ting-ting.Comparison of Clinical Effects of Interventional Treatment of Coronary Heart Disease by Femoral and Radial Artery[J].Medical Information,2018,(13):114.[doi:10.3969/j.issn.1006-1959.2018.03.038]
[4]迮艳华.稳心颗粒联合美托洛尔治疗冠心病心律失常的疗效分析[J].医学信息,2018,(03):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
 ZE Yan-hua.Therapeutic Effect of Wenxin Granule Combined with Metoprolol on Arrhythmia of Coronary Heart Disease[J].Medical Information,2018,(13):139.[doi:10.3969/j.issn.1006-1959.2018.03.049]
[5]张 旭.冠心病心绞痛患者进行护理干预的临床效果及 对护理质量影响研究[J].医学信息,2018,(05):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
 ZHANG Xu.Clinical Effect of Nursing Intervention in Patients with Angina Pectoris of Coronary Heart Disease and its Influence on Nursing Quality[J].Medical Information,2018,(13):182.[doi:10.3969/j.issn.1006-1959.2018.05.068]
[6]向明明,赵晓辉.黑龙江省东部地区汉族人群冠心病的危险因素研究[J].医学信息,2018,(07):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
 XIANG Ming-ming,ZHAO Xiao-hui.Study on Risk Factors of Coronary Heart Disease in Han Nationality Population in Eastern Heilongjiang Province[J].Medical Information,2018,(13):122.[doi:10.3969/j.issn.1006-1959.2018.07.041]
[7]王 坤,张永春.血清胆红素水平、单核细胞数、红细胞分布宽度与 冠状动脉病变程度的关系[J].医学信息,2018,(08):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
 WANG Kun,ZHANG Yong-chun.Relationship between Serum Bilirubin Level,Monocyte Count,Red Blood Cell Distribution Width and Severity of Coronary Artery Disease[J].Medical Information,2018,(13):53.[doi:10.3969/j.issn.1006-1959.2018.08.017]
[8]程 林.重组人脑利钠肽用于重症急性心肌炎伴 心力衰竭患者治疗的临床研究[J].医学信息,2018,(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
 CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,(13):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[9]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
 HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,(13):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[10]毛红岩.冠状动脉介入治疗冠心病的疗效及 对患者血清炎症因子的影响[J].医学信息,2018,(10):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
 MAO Hong-yan.Effect of Coronary Intervention on Coronary Heart Disease and its Influence on Serum Inflammatory Factors[J].Medical Information,2018,(13):77.[doi:10.3969/j.issn.1006-1959.2018.10.023]
[11]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
 LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,(13):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]

更新日期/Last Update: 2018-07-01